{
    "clinical_study": {
        "@rank": "134400", 
        "arm_group": {
            "arm_group_label": "Midazolam and GLPG0634", 
            "arm_group_type": "Experimental", 
            "description": "Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8) and multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8."
        }, 
        "brief_summary": {
            "textblock": "This will be a drug-drug interaction study to evaluate the effect of multiple oral doses of\n      GLPG0634 on the single dose pharmacokinetic profile of midazolam administered in fasted\n      normal healthy males. Each subject will receive a single oral dose of midazolam (2 mg) on 2\n      occasions: on Day 1, before dosing with GLPG0634 and on Day 8, after multiple oral doses of\n      GLPG0634 (daily for 7 days).\n\n      Also, the safety and tolerability of multiple oral doses of GLPG0634 co-administered with\n      midazolam in healthy male subjects will be evaluated."
        }, 
        "brief_title": "A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  male, between 40 and 60 years of age, inclusive\n\n          -  within BMI range 18 to 30 kg/m2, inclusive\n\n        Exclusion Criteria:\n\n          -  Any condition that might interfere with the procedures or tests in this study\n\n          -  Drug or alcohol abuse\n\n          -  Smoking"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798979", 
            "org_study_id": "GLPG0634-CL-103"
        }, 
        "intervention": [
            {
                "arm_group_label": "Midazolam and GLPG0634", 
                "description": "Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.", 
                "intervention_name": "GLPG0634", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Midazolam and GLPG0634", 
                "description": "Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Midazolam"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }, 
                "name": "Covance Clinical Research Unit"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Open Interaction Study Between Oral Doses of GLPG0634 (200 mg QD) and Single Oral Doses of Midazolam (2 mg) in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Galapagos NV", 
            "last_name": "Fr\u00e9d\u00e9ric Vanhoutte, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To characterize the amount of (1'-OH) Midazolam in plasma over time before and after multiple doses of GLPG0634 - pharmacokinetics (PK) - in healthy subjects", 
            "measure": "The amount of (1'-OH) Midazolam in plasma over time before and after multiple oral doses of GLPG0634", 
            "safety_issue": "No", 
            "time_frame": "Between predose and up to 24h postdose on Day 1 and Day 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798979"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To characterize the amount of GLPG0634 and metabolite in plasma over time after multiple doses of GLPG0634 (and co-administration of Midazolam on Day 8) - pharmacokinetics (PK) - in healthy subjects", 
                "measure": "The amount of GLPG0634 and metabolite in plasma over time after multiple oral doses of GLPG0634 (and co-administration of Midazolam on Day 8)", 
                "safety_issue": "No", 
                "time_frame": "Between predose (Day 2) and up to 96h after the last dose on Day 8 (on Day 12)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 after multiple oral doses in healthy subjects with or without coadministration of Midazolam in terms of the number of adverse events reported", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Between screening and 7-10 days after the last dose of GLPG0634 (Day 15-18)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 after multiple oral doses in healthy subjects with or without coadministration of Midazolam in terms of changes in vital signs as measured by pulse, supine blood pressure, oral temperature (and respiratory rate) reported", 
                "measure": "Changes in vital signs as measured by pulse, supine blood pressure, oral temperature (and respiratory rate only 1 hour post Midazolam dosing)", 
                "safety_issue": "Yes", 
                "time_frame": "Between screening and 7-10 days after the last dose of GLPG0634 (Day 15-18)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 after multiple oral doses in healthy subjects with or without coadministration of Midazolam in terms of changes in 12-ECG measures reported", 
                "measure": "Changes in 12-lead ECG measures", 
                "safety_issue": "Yes", 
                "time_frame": "Between screening and 7-10 days after the last dose of GLPG0634 (Day 15-18)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 after multiple oral doses in healthy subjects with or without coadministration of Midazolam in terms of changes in physical examination reported", 
                "measure": "Changes in physical exam measures", 
                "safety_issue": "Yes", 
                "time_frame": "Between screening and 7-10 days after the last dose of GLPG0634 (Day 15-18)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 after multiple oral doses in healthy subjects with or without coadministration of Midazolam in terms of changes in blood safety lab parameters reported", 
                "measure": "Changes in blood safety lab parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Between screening and 7-10 days after the last dose of GLPG0634 (Day 15-18)"
            }, 
            {
                "description": "To evaluate the safety and tolerability of GLPG0634 after multiple oral doses in healthy subjects with or without coadministration of Midazolam in terms of changes in urine safety lab parameters reported", 
                "measure": "Changes in urine safety lab parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Between screening and 7-10 days after the last dose of GLPG0634 (Day 15-18)"
            }
        ], 
        "source": "Galapagos NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galapagos NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}